Expression of angiogenic factors in craniopharyngiomas: Implications for tumor recurrence

Neurosurgery

Volumn 66, Issue 4, 2010, Pages 744-750

  Sun, Halil Ibrahim ^a   Akgun, Emel ^a   Bicer, Atilla ^a   Ozkan, Abdulkadir ^a   Bozkurt, Suheyla Uyar ^a   Kurtkaya, Ozlem ^a   Koc, Demet Yalcinkaya ^a   Pamir, M Necmettin ^a   Kilic, Turker ^a  

^a MARMARA UNIVERSITY   (Turkey)

Author keywords

Craniopharyngioma; Fibroblast growth factor 2; Platelet derived growth factor; Platelet derived growth factor receptors; Tumor angiogenic potential; Tumor recurrence

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; FIBRONECTIN; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; VASCULOTROPIN;

ADULT; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORNEA; CRANIOPHARYNGIOMA; EXCISION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TREATMENT OUTCOME; TUMOR LOCALIZATION; TUMOR RECURRENCE;

ADULT; ANGIOGENESIS INDUCING AGENTS; ANIMALS; CORNEA; CRANIOPHARYNGIOMA; DISEASE MODELS, ANIMAL; FEMALE; FIBROBLAST GROWTH FACTOR 2; FIBRONECTINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM TRANSPLANTATION; PITUITARY NEOPLASMS; PLATELET-DERIVED GROWTH FACTOR; RATS; RATS, SPRAGUE-DAWLEY; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 77950001044     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.NEU.0000367553.65099.14     Document Type: Article

References (48)

1. Rutka JT. Craniopharyngioma. J Neurosurg. 2002;97(1):1-2.
2. Bunin GR, Surawicz TS, Witman PA, Preston-Martin S, Davis F, Bruner JM. The descriptive epidemiology of craniopharyngioma. J Neurosurg. 1998;89(4):547-551.
3. Betsholtz C. Biology of platelet-derived growth factors in development. Birth Defects Res C Embryo Today. 2003;69(4):272-285.
4. Zagzag D. Angiogenic growth factors in neural embryogenesis and neoplasia. Am J Pathol. 1995;146(2):293-309.
5. Hoffman HJ, Hendrick EB, Humphreys RP, Buncic JR, Armstrong DL, Jenkin RD. Management of craniopharyngioma in children. J Neurosurg. 1977;47(2):218-227.
6. Crotty TB, Scheithauer BW, Young WF Jr, et al. Papillary craniopharyngioma: a clinicopathological study of 48 cases. J Neurosurg. 1995;83(2):206-214.
7. Caldarelli M, di Rocco C, Papacci F, Colosimo C Jr. Management of recurrent craniopharyngioma. Acta Neurochir (Wien). 1998;140(5):447-454.
8. Duff JM, Meyer FB, Ilstrup DM, Laws ER, Schleck CD, Scheithauer BW. Longterm outcomes for surgically resected craniopharyngiomas. Neurosurgery. 2000;46(2):291-305.
9. Regine WF, Mohiuddin M, Kramer S. Long-term results of pediatric and adult craniopharyngiomas treated with combined surgery and radiation. Radiother Oncol. 1993;27(1):13-21.
10. Ausprunk DH, Folkman J. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res. 1977;14(1):53-65.
11. Patan S, Munn LL, Jain RK. Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: a novel mechanism of tumor angiogenesis. Microvasc Res. 1996;51(2):260-272.
12. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascularspecific growth factors and blood vessel formation. Nature. 2000;407(6801):242-248.
13. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285(21):1182-1186.
14. Gasparini G, Harris AL. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol. 1995;13(3):765-782.
15. Hanahan D. Signaling vascular morphogenesis and maintenance. Science. 1997;277(5322):48-50.
16. Lamszus K, Heese O, Westphal M. Angiogenesis-related growth factors in brain tumors. Cancer Treat Res. 2004;117:169-190.
17. Weidner N. Tumour vascularity and proliferation: clear evidence of a close relationship. J Pathol. 1999;189(3):297-299.
18. Choi HJ, Hyun MS, Jung GJ, Kim SS, Hong SH. Tumor angiogenesis as a prognostic predictor in colorectal carcinoma with special reference to moDeof metastasis and recurrence. Oncology. 1998;55(6):575-581.
19. Engel CJ, Bennett ST, Chambers AF, Doig GS, Kerkvliet N, O,Malley FP. Tumor angiogenesis predicts recurrence in invasive colorectal cancer when controlled for Dukes staging. Am J Surg Pathol. 1996;20(10):1260-1265.
20. Vaquero J, Zurita M, DeOya S, Coca S, Morales C, Salas C. Expression of vascular permeability factor in craniopharyngioma. J Neurosurg. 1999;91(5):831-834.
21. Vidal S, Kovacs K, Lloyd RV, Meyer FB, Scheithauer BW. Angiogenesis in patients with craniopharyngiomas: correlation with treatment and outcome. Cancer. 2002; 94(3):738-745.
22. Xu J, Zhang S, You C, Wang X, Zhou Q. Microvascular density and vascular endothelial growth factor have little correlation with prognosis of craniopharyngioma. Surg Neurol. 2006;66(suppl 1):S30-S34.
23. Pietras K, Sjöblom T, Rubin K, Heldin CH, Ostman A. PDGF receptors as cancer drug targets. Cancer Cell. 2003;3(5):439-443.
24. Lim M, Cheshier S, Steinberg GK. New vessel formation in the central nervous system during tumor growth, vascular malformations, and Moyamoya. Curr Neurovasc Res. 2006;3(3):237-245.
25. Konya D, Yildirim O, Kurtkaya O, et al. Testing the angiogenic potential of cerebrovascular malformations by use of a rat cornea model: usefulness and novel assessment of changes over time. Neurosurgery. 2005;56(6):1339-1346.
26. Bunin GR, Surawicz TS, Witman PA, Preston-Martin S, Davis F, Bruner JM. The descriptive epidemiology of craniopharyngioma. Neurosurg Focus. 1997;3(6):e1.
27. Adamson TE, Wiestler OD, Kleihues P, Yáargil MG. Correlation of clinical and pathological features in surgically treated craniopharyngiomas. J Neurosurg. 1990; 73(1):12-17.
28. Alvarez M. Craniopharyngiomas. J Neurosci Nurs. 2006;38(5):362-368.
29. Backlund EO. Treatment of craniopharyngiomas: the multimodality approach. Pediatr Neurosurg. 1994;21(suppl 1):82-89.
30. Hofmann BM, Hlavac M, Martinez R, BuchfelDerM, Muller OA, Fahlbusch R. Long-term results after microsurgery for Cushing disease: experience with 426 primary operations over 35 years. J Neurosurg. 2008;108(1):9-18.
31. Motegi H, Kuroda S, IshII N, et al. De novo formation of cavernoma after radiosurgery for adult cerebral arteriovenous malformation: case report. Neurol Med Chir (Tokyo). 2008;48(9):397-400.
32. Agozzino L, Ferraraccio F, Accardo M, Esposito S, Agozzino M, Cuccurullo L. Morphological and ultrastructural findings of prognostic impact in craniopharyngiomas. Ultrastruct Pathol. 2006;30(3):143-150.
33. Dunn IF, Heese O, Black PM. Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs. J Neurooncol. 2000;50(1-2):121-137.
34. Kiliç T, Pamir MN, Küllü S, Eren F, Ozek MM, Black PM. Expression of structural proteins and angiogenic factors in cerebrovascular anomalies. Neurosurgery. 2000; 46(5):1179-1192.
35. Seker A, Yildirim O, Kurtkaya O, et al. Expression of integrins in cerebral arteriovenous and cavernous malformations. Neurosurgery. 2006;58(1):159-168.
36. Shih AH, Dai C, Hu X, Rosenblum MK, Koutcher JA, Holland EC. Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res. 2004;64(14):4783-4789.
37. Kiliç T, Bayri Y, Ozduman K, et al. Tenascin in meningioma: expression is correlated with anaplasia, vascular endothelial growth factor expression, and peritumoral edema but not with tumor borDershape. Neurosurgery. 2002;51(1):183-193.
38. Miraux S, Lemiere S, Pineau R, et al. Inhibition of FGF receptor activity in glioma implanted into the mouse brain using the tetracyclin-regulated expression system. Angiogenesis. 2004;7(2):105-113.
39. Machein MR, Plate KH. VEGF in brain tumors. J Neurooncol. 2000;50(1-2):109-120.
40. Hu Y, Schett G, Zou Y, Dietrich H, Xu Q. Abundance of platelet-derived growth factors (PDGFs), PDGF receptors and activation of mitogen-activated protein kinases in brain decline with age. Brain Res Mol Brain Res. 1998;53(1-2):252-259.
41. Mentlein R, Held-Feindt J. Angiogenesis factors in gliomas: a new key to tumour therapy? Naturwissenschaften. 2003;90(9):385-394.
42. Morioka I, Tsuneishi S, Takada S, Matsuo M. PDGF-alpha receptor expression following hypoxic-ischemic injury in the neonatal rat brain. Kobe J Med Sci. 2004; 50(1-2):21-30.
43. Todo T, Adams EF, Fahlbusch R, Dingermann T, Werner H. Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor. J Neurosurg. 1996;84(5):852-859.
44. Zhang FX, Hutchins JB. Expression of platelet-derived growth factor (PDGF) receptor alpha-subunit in mouse brain: comparison of Patch mutants and normal littermates. Cell Mol Neurobiol. 1996;16(4):479-487.
45. Fakhrai N, Neophytou P, Dieckmann K, et al. Recurrent spinal ependymoma showing partial remission unDerimatinib. Acta Neurochir (Wien). 2004;146(11):1255-1258.
46. Bihorel S, Camenisch G, Gross G, Lemaire M, Scherrmann JM. Influence of hydroxyurea on imatinib mesylate (Gleevec) transport at the mouse blood-brain barrier. Drug Metab Dispos. 2006;34(12):1945-1949.
47. Kilic T, Alberta JA, Zdunek PR, et al. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res. 2000;60(18):5143-5150.
48. Wen PY, Yung WK, Lamborn KR, et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res. 2006;12(16):4899-4907.